Research Paper Volume 11, Issue 9 pp 2551—2564
MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway
Figure 7. MiR-124 enhanced the cytotoxicity of cisplatin to CD133+ HCC tumors in vivo. (A) Tumor growth of CD133+ HepG2 tumors treated with cisplatin (5 mg/kg). (B) Separated tumors after 28 days inoculation. (C) Expression of miR-124 in resected tumor tissues. *P<0.05 vs. LT-empty. #P<0.05 vs. LT-empty + cisplatin group. (D) Expression of SIRT1 and phosphorylated JNK in resected tumor tissues. *P<0.05 vs. LT-empty. #P<0.05 vs. LT-empty + cisplatin group.